Drug Sensitivity and Mutation Profiling

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

14 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-17

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective, non-randomized observational study. Freshly isolated tumor cells will be tested for chemosensitivity to the standard of care drugs as single agents and in combinations using state-of-the-art viability assay designed for ex-vivo high-throughput drug sensitivity testing (DST). In addition, the genetic profile of the tumor will be obtained from the medical records and correlated with drug response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

NCT03860376

Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Large Cell Lymphoma +11 more

COMPLETED

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969

Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Large Cell Lymphoma +15 more

RECRUITING PHASE1

Evaluating the Side Effects and How Well Anticancer Drugs Work in Very Young Patients With Cancer

NCT00897871

Unspecified Childhood Solid Tumor, Protocol Specific

UNKNOWN

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

NCT00674193

Childhood Acute Lymphoblastic Leukemia Childhood Rhabdomyosarcoma Childhood Soft Tissue Sarcoma +5 more

COMPLETED

Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study

NCT00001217

Osteosarcoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The excised tumors or a biopsy will be interrogated for sensitivity or resistance to FDA-approved and/or available investigational agents. In addition, normal samples (blood or buccal swab) will be collected for genetic analysis of germline mutations and cancer predisposition markers. The timeframe between the sample acquisition and ex vivo DST results return will be approximately 5-10 working days. All drugs tested in the DST assay will be assigned a hybrid score reflecting the tumor's sensitivity and drug toxicity.

This is an observational study and not a treatment protocol. It will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ewing Sarcoma Osteosarcoma Rhabdomyosarcoma Wilms Tumor Sarcoma, Spindle Cell Sarcoma Rhabdoid Childhood Sarcoma of Soft Tissue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with newly diagnosed as well as relapsed/refractory sarcomas.

The investigators intend to enroll newly diagnosed or refractory/relapsed pediatric patients with all types of sarcomas where tumor tissue would be available for ex vivo drug screening and genomic profiling. This observational study will assess how ex vivo drug testing and mutation profiling may predict clinical outcomes (response, survival, or relapse). The treating physician will decide which of the standard treatment options is appropriate independent of the DST results. The results of DST will not be available to the treating physician at the time of decision on the treatment regimen. DST will include all drugs from the standard treatment regimens available for all types of sarcomas

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 21 years or younger at the time of enrollment on this study of any gender, race, or ethnicity.
* Subjects with suspected or confirmed diagnosis of all types of sarcomas.
* Subjects who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers).
* Subjects are willing to have a blood draw or buccal swab done for the purposes of genetic testing.
* Subjects or their parents or legal guardians willing to sign informed consent.
* Subjects aged 7 to 17 willing to sign assent.

Exclusion Criteria

* Subjects who do not have malignant tissue available and accessible.
* The amount of excised malignant tissue is not sufficient for ex vivo drug testing and/or genetic profiling.
* Patients with other types of tumors and tumors that have a high (\>90%) cure rate with safe standard therapy.

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No